On June 25, 2024 Manhattan BioSolutions, Inc. (MABS), an emerging biotech company developing new classes of precision biologics for the treatment of advanced cancers, and the Institute of Chemical Biology & Drug Discovery (ICB&DD) at Stony Brook University, led by University Distinguished Professor Iwao Ojima, reported to have signed a Letter of Intent (LOI) to establish a collaboration to develop next-generation antibody-drug conjugate (ADC) therapeutics for the treatment of solid tumors with high unmet medical need (Press release, Manhattan BioSolutions, JUN 25, 2024, View Source [SID1234644530]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The joint research program leverages the ICB&DD’s cutting-edge medicinal chemistry platforms, including novel fluorine-containing taxoid payloads with superior potency against drug-resistant cancers and a versatile tumor-targeting drug delivery system utilizing a triazine-based tripod linker. These innovative technologies, protected by patent applications filed by The Research Foundation of the State University of New York, have the potential to enhance the efficacy and selectivity of ADCs. MABS seeks to evaluate these technologies for potential use in its proprietary ADC program targeting a novel tumor-associated glycoprotein that is highly expressed across multiple aggressive solid tumor types while showing limited expression in healthy tissues.
"We are excited to collaborate with the ICB&DD to explore the potential of their innovative technologies in the context of ADC therapy," said Dr. Borys Shor, CEO of Manhattan BioSolutions. "This partnership brings together our deep experience in ADC development with the innovative taxoid platforms pioneered by Professor Ojima, creating an opportunity to address the limitations of current ADC therapies."
The MABS and ICB&DD teams will work together to design and evaluate novel ADC candidates with the goal of identifying a promising lead for advancement to preclinical development.